Swedish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
15 resultat
Use of N-acetyl-D-glucosamine in the manufacture of pharmaceutical useful for treating cardio-cerebrovascular anoxemia
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
TECHNICAL FIELD
The present invention relates to the use of N-acetyl-D-glucosamine and pharmaceutical acceptable salts thereof in the manufacture of a medicament for resisting cardiac and cerebral ischemia as well as oxygen-deficiency.
BACKGROUND ART
The cardiac and cerebral ischemia as well as
Prodrug salts
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
TECHNICAL FIELD
Provided are novel prodrug salts of selective aquaporin inhibitors, e.g., of aquaporin-4 and/or aquaporin-2, of Formula I as described below, their use as pharmaceuticals and pharmaceutical compositions comprising them, and novel intermediates used in and novel processes for their
Prodrug salts
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
TECHNICAL FIELD
Provided are novel prodrug salts of selective aquaporin inhibitors, e.g., of aquaporin-4 and/or aquaporin-2, of Formula I as described below, their use as pharmaceuticals and pharmaceutical compositions comprising them, and novel intermediates used in and novel processes for their
Protein S protects the nervous system from injury
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND OF THE INVENTION
This invention relates to the use of protein S and/or variants thereof as neuroprotective agents for treating brain disorders and other pathological conditions. The ability of protein S and variants thereof to act as cell survival factors on cells of the nervous systems
Method of treating migraine headache without aura
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
TECHNICAL FIELD OF THE INVENTION
The present invention relates to methods and compositions for treating selected conditions of the central and peripheral nervous systems employing non-synaptic mechanisms. More specifically, one aspect of the present invention relates to methods and compositions for
Methods and compositions for treating conditions of the central and peripheral nervous systems using non-synaptic mechanisms
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
TECHNICAL FIELD OF THE INVENTION
The present invention relates to methods and compositions for treating selected conditions of the central and peripheral nervous systems employing non-synaptic mechanisms. More specifically, one aspect of the present invention relates to methods and materials for
Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
The present invention relates to the field of ophthalmology. In particular, the present invention relates to the treatment of retinal tissues. More specifically, the present invention discloses compositions and methods of using adenosine uptake inhibitors in the prevention or treatment of retinal
15-nitro-2.beta., 3.beta.-dihydro- and 15-nitro-2.beta.,3.beta.,6,7-tetrahydrotabersonine derivatives, pharmaceutical compositions containing them and process for preparing same
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
The invention relates to novel 15-nitro-2.beta., 3.beta.-dihydro-and 15-nitro-2.beta., 3.beta., 6, 7-tetrah (according to the Chemical Abstracts' nomenclature 15-nitro-(2.alpha., 5.alpha., 12.beta., 19.alpha.)-aspidospermidine-3.alpha.-carboxylic acid derivatives) of the formula (I), ##STR2##
Substituted saturated aza heterocycles as inhibitors of nitric oxide synthase
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
CROSS REFERENCE TO RELATED APPLICATION
The present invention is based on, and claims priority from 60/008,390, filed Dec. 8, 1995.
BACKGROUND OF THE INVENTION
This application is directed to inhibitors of nitric oxide synthase, and in particular substituted azacycle derivatives.
Nitric Oxide in
Cyclic amidine analogs as inhibitors of nitric oxide synthase
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND OF THE INVENTION
This application is directed to inhibitors of Nitric oxide synthase, and in particular cyclic amidines.
Nitric Oxide in Biology.
The emergence of nitric oxide (NO), a reactive, inorganic radical gas as a molecule contributing to important physiological and pathological
Aminoadamantane derivatives as therapeutic agents
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND OF THE INVENTION
Certain adamantane derivatives have been used to treat illnesses. Rimantadine (1-(1-aminoethyl)adamantane) is used for the prophylaxis and treatment of influenza in humans. Amantadine has been used for the treatment of both influenza and Parkinson's disease (Schwab et
Aminoadamantane derivatives as therapeutic agents
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND OF THE INVENTION
Certain adamantane derivatives have been used to treat illnesses. Rimantadine (1-(1-aminoethyl)adamantane) is used for the prophylaxis and treatment of influenza in humans. Amantadine has been used for the treatment of both influenza and Parkinson's disease (Schwab et
Aminoadamantane derivatives as therapeutic agents
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND OF THE INVENTION
Certain adamantane derivatives have been used to treat illnesses. Rimantadine (1-(1-aminoethyl)adamantane) is used for the prophylaxis and treatment of influenza in humans. Amantadine has been used for the treatment of both influenza and Parkinson's disease (Schwab et
Neuro-protective agents and uses thereof
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a U.S. National Stage Application under 35 U.S.C. .sctn. 371 of International Application No. PCT/CN2015/076528, filed Apr. 14, 2015, which application claims priority to Chinese Patent Application No. 201410170263.7 filed Apr. 25, 2014,
Endogenous nitric oxide synthesis under conditions of low oxygen tension
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF THE INVENTION
The present invention describes novel methods to induce synthesis of endogenous nitric oxide or endothelium-derived relaxing factor, and methods for maintaining levels of nitric oxide under hypoxic conditions. One aspect of the invention relates to novel methods to induce
Den mest kompletta databasen med medicinska örter som stöds av vetenskapen
- Fungerar på 55 språk
- Växtbaserade botemedel som stöds av vetenskap
- Örter igenkänning av bild
- Interaktiv GPS-karta - märka örter på plats (kommer snart)
- Läs vetenskapliga publikationer relaterade till din sökning
- Sök efter medicinska örter efter deras effekter
- Organisera dina intressen och håll dig uppdaterad med nyheterna, kliniska prövningar och patent
Skriv ett symptom eller en sjukdom och läs om örter som kan hjälpa, skriv en ört och se sjukdomar och symtom den används mot.
* All information baseras på publicerad vetenskaplig forskning
